[Plasma proteasome 20S activity in children treated for acute lymphoblastic leukaemia].
THE AIM of our study was: to determine the proteasome 20S activity in plasma of patients treated for acute lymphoblastic leukaemia.


METHODS
Plasma proteasome activity was measured in children (n=16) at two points: at diagnosis and on the 33rd day using the spectrophotometric method with peptidic substrate and selective proteasome activator 0.03% SDS.


RESULTS
1. At diagnosis we observed high activity of the proteasome 20S in comparison to control (p<0.005). After haematological remission the proteasome 20S activity lowered by about 50% (p<0.05). 3. We did not find the influence of immunophenotype, initial leucocytosis, LDH activity and hepatosplenomegaly on initial proteasome values.


CONCLUSIONS
Dynamic changes of the proteasome 20S activity confirm its participation in cancerogenic process. Proteasome 20S activity may be an effective indicator in the monitoring of anticancer treatment.
Leszczyńska
Elzbieta
E
Klinika Onkologii Dzieciecej, Akademia Medyczna, ul. Waszyngtona 17, 15-274 Białystok, Poland. eleszcz@mp.pl
Ostrowska
Halina
H
Krawczuk-Rybak
Maryna
M
D000293:Adolescent; D015415:Biomarkers; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000175:diagnosis*; D046988:Proteasome Endopeptidase Complex / Q000097:blood*; D013053:Spectrophotometry
D015415:Biomarkers; D046988:Proteasome Endopeptidase Complex